Phase 2 Completed N=45 Randomized Double-blind Prevention

Evaluation of Nicotinamide Riboside in Prevention of Small Fiber Axon Degeneration and Promotion of Nerve Regeneration

Small Fiber Neuropathy

Source: ClinicalTrials.gov NCT03912220 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Jun 2024

Primary outcomePrimary: Denervation of Skin — 0.1; 0.1 percent change — p=0.33

Summary

This study will evaluate the effects of a nutritional supplement called nicotinamide riboside in preventing small fiber nerve degeneration that is experimentally induced by applying capsaicin to skin in otherwise healthy study participants. Furthermore, the effects on nerve regeneration will also be evaluated. The results will be compared to a placebo control drug.

Outcome Measures

Outcome	Result	p-value
PRIMARY Denervation of Skin	0.1; 0.1	0.33
PRIMARY Reinnervation of Skin	7.4; 7.3	0.54

Eligibility Criteria

Inclusion Criteria

Age: 18-65
BMI<32
Normal neurological examination defined as Neuropathy Impairment Score <2

Exclusion Criteria

History of peripheral neuropathy
Any peripheral neuropathy risk factor including diabetes, Vitamin B12 deficiency, HIV-infection, chronic kidney or hepatic disease, hypothyroidism, chemotherapy or other know neurotoxic exposure.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT03912220). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.